Flynn as foreign agent no surprise to Trump team
National security adviser was fired over conversations with Russian ambassador
WASHINGTON (AP) — U.S. President Donald Trump’s transition team learned before the inauguration that incoming National Security Adviser Michael Flynn might register with the government as a foreign agent, White House officials acknowledged Friday.
The disclosure suggests Trump transition lawyers did not view Flynn’s lobbying work for a Turkish businessman as a liability for an official who serves as the president’s closest adviser on security and international affairs. It also raises new questions about whether Trump’s transition team, and later his White House lawyers, fully vetted Flynn.
Flynn’s registration this week with the Justice Department disclosed lobbying by him and his firm that may have benefited the government of Turkey.
Trump fired Flynn last month on other grounds — that he misled Vice-President Mike Pence and other White House officials about his conversations with Russia’s ambassador to the U.S. Flynn’s registration comes amid intense scrutiny over potential contacts with Russia. The FBI is investigating, as are House and Senate intelligence committees.
Flynn registered with the Justice Department on Tuesday, citing $530,000 worth of lobbying. His work on behalf of a company owned by Turkish businessman Ekim Alptekin occurred at the same time he was advising Trump’s presidential campaign.
White House spokesman Sean Spicer said Trump had not been aware Flynn might register as a foreign agent. He said Flynn’s lawyer had raised the possible filing with the transition team, but Trump’s attorneys said it was a personal matter and not something they would consult on.
“It’s a business matter; it’s not something that would be appropriate for a government entity to give someone guidance on when they should file as an individual,” Spicer said. He dismissed questions about whether Flynn’s work should have raised red flags for the new administration, saying the retired Army lieutenant general had “impeccable credentials.”
Among those told of Flynn’s lobbying work during the transition was Don McGahn, a campaign lawyer who has gone on to become White House counsel.
A White House official said McGahn and others were not aware of the details of Flynn’s work. It’s not clear why the Trump advisers did not seek additional information once Flynn’s lawyers raised the potential filing.
According to the person with knowledge of the discussions, Flynn’s representatives had a second conversation with Trump lawyers after the inauguration and made clear the national security adviser would indeed be registering with the Justice Department. The White House official said the counsel’s office had no recollection of that second discussion.
Both the White House official and person with knowledge of the discussions insisted on anonymity in order to disclose the private conversations.
In the filings with the Justice Department’s Foreign Agent Registration Unit, Flynn and his firm, Flynn Intel Group, Inc., acknowledged that his work for Alptekin’s company “could be construed to have principally benefited the Republic of Turkey.” The lobbying on behalf of Inovo BV, a Dutchbased company owned by Alptekin, occurred from August through November.
Former FDA official to head food and drug agency
WASHINGTON — President Donald Trump announced Friday that he has chosen a conservative doctor-turned-pundit with deep ties to Wall Street and the pharmaceutical industry to lead the powerful Food and Drug Administration. A Senate vote is still required. Dr. Scott Gottlieb would be tasked with Trump’s goal of cutting red tape at the FDA, which regulates everything from pharmaceuticals to seafood to electronic cigarettes. Trump has called the FDA’s drug approval process “slow and burdensome” despite changes to speed reviews, particularly of cutting-edge products.
Gottlieb, 44, is no stranger to the FDA — he served as a deputy commissioner under President George W. Bush. While he has frequently criticized the FDA for unnecessary regulations and urged changes to get safe and effective drugs onto the market faster, he has supported its overall mission.
Gottlieb is a resident fellow at the conservative American Enterprise Institute and a partner in the venture capital firm New Enterprise Associates. He has spent more than a decade in Washington with government, health policy consulting and political think tanks.